FGF23 and hypophosphatemia: Although currently burosumab, an antibody blocking FGF23 effects, is clinically available for patients with primary increased FGF23 associated with hypophosphatemia, [38,39], its use may be risky in CKD, because of concomitant aggravation of hyperphosphatemia.